Nerea Martin Almazan

Oct 3, 2024 | biorxiv.org | Sara Alexia Roman |Sara Campos Román |Yizhe Sun |Lars Bräutigam |Nerea Martin Almazan

AbstractBackground: Immune therapies are emerging as a critical component of cancer treatment, capable of delivering durable and potentially curative responses. While CAR-T cell therapy has proven effective for hematological malignancies, it faces challenges in treating solid tumors due to tumor antigen heterogeneity, an immunosuppressive tumor microenvironment, and physical barriers hindering CAR-T cell infiltration.